Bayer will pay up to $7.25 billion to settle the lawsuits over its weedkiller Roundup — one of the largest mass-tort settlements in American history. A Missouri judge approved the nationwide class settlement on Friday, November 20, 2026, ending, for now, a decade of litigation that has weighed on the German company since it bought Monsanto in 2018. The settlement covers thousands of Americans who say they developed non-Hodgkin lymphoma, a form of blood cancer, after using Roundup — people already ill, and people who become ill in the future. Individual payouts will average between $10,000 and $165,000, depending on how the person used the product, how old they were when diagnosed, and how severe their illness is. And through all of it, Bayer's position has not changed: the company denies that Roundup causes cancer.
The approval came from St. Louis Circuit Judge Timothy Boyer, who found the settlement 'fair, reasonable, and adequate' and said the total dollar amount is 'among the largest in the history of mass tort personal-injury class action settlements.' The settlement was filed in St. Louis Circuit Court in Missouri, home to Bayer's North America crop science division and the state where many of the lawsuits were brought. It calls for Monsanto, Bayer's subsidiary, to make declining capped annual payments into a special fund for up to 21 years, totalling as much as $7.25 billion, including payments already made. The approved settlement also includes $600 million for attorneys' fees. Bayer chief executive Bill Anderson called the court-approved settlement 'a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation.'
Who qualifies is the part that matters to the people the settlement is actually for. The settlement covers two groups. The first is people who were exposed to Roundup before February 17, 2026, and already have a medical diagnosis of non-Hodgkin lymphoma. The second is people who receive a diagnosis of non-Hodgkin lymphoma before the end of a 16-year period following final approval of the agreement — the future cases, which are what make this settlement different from an ordinary payout. The amount any one person receives depends on how they used the product, their age at diagnosis, and the severity of their illness. The judge's written judgment noted the risk on the other side of the decision too: he said there was a risk Bayer would have filed for bankruptcy protection if the settlement had been rejected, which would have left claimants with far less. The decision is subject to appeal.
The settlement lands in a legal landscape that shifted sharply in Bayer's favour this year. In June, the U.S. Supreme Court ruled in the Durnell case that the Federal Insecticide, Fungicide, and Rodenticide Act preempts 'failure-to-warn' cases brought in state court — the exact kind of claim at the heart of most Roundup lawsuits. Judge Boyer cited that ruling in finding the settlement adequate. Bayer's own statement described the class settlement and the Durnell ruling as 'mutually reinforcing pillars' in its strategy to contain the Roundup litigation. For the company, the settlement provides something it has wanted for years: financial certainty against mounting litigation costs that had led it to contemplate pulling Roundup from U.S. agricultural markets altogether.
That certainty is exactly what the settlement does not give to the science. Nothing in the judge's approval decides whether Roundup causes cancer. Bayer denies it does; the plaintiffs' lawyers say it does; regulators and courts have split on the question for years. What the settlement decides is money and process: a fund, a schedule, a set of rules for who gets paid and how much, and an end — for the claims it covers — to the lawsuits. For the thousands of people who used Roundup and then received a lymphoma diagnosis, the practical question is not the science but the claim: whether they are in the class, and what their case is worth under the settlement's formula.
THE KEY NUMBERS
$7.25 billion — the maximum Bayer will pay, over up to 21 years of annual payments into a special fund. $10,000 to $165,000 — the average range of individual payouts, by use, age at diagnosis and severity. $600 million — the attorneys' fees included in the settlement. 21 years — the maximum payment schedule. 16 years — the window after final approval during which future non-Hodgkin lymphoma diagnoses are covered. February 17, 2026 — the exposure cutoff for the settlement class. November 20, 2026 — the day Judge Timothy Boyer of the St. Louis Circuit Court approved it. June 2026 — the Supreme Court's Durnell ruling, which limited failure-to-warn lawsuits and shaped the settlement. 2018 — the year Bayer bought Monsanto and inherited the Roundup litigation.
THE STORY SO FAR
2018: Bayer buys Monsanto for $63 billion and inherits the Roundup lawsuits. Over the following years, tens of thousands of claims are filed by people who say they developed non-Hodgkin lymphoma after using Roundup, which Bayer says does not cause cancer. The litigation drags on for close to a decade, with mounting costs leading Bayer to contemplate pulling Roundup from U.S. agricultural markets. June 2026: the U.S. Supreme Court rules in Durnell that federal pesticide law preempts state failure-to-warn claims. Later in 2026: a jury returns a unanimous defense verdict in Aretino, the first Roundup case tried since Durnell. November 20, 2026: Judge Timothy Boyer grants final approval to the $7.25 billion settlement, calling it 'fair, reasonable, and adequate' and warning that rejecting it risked a Bayer bankruptcy filing.
WHAT HAPPENS NEXT
The approval order is subject to appeal, so the settlement is not final until the appeal window closes — and objectors to class settlements do appeal, so a challenge is possible. If it stands, Monsanto begins the annual payments into the fund, and the claims programme opens for the two groups it covers: people already diagnosed, and people diagnosed within the 16-year window. For anyone who believes they qualify, the next step is to check the settlement's claims process through their lawyer or the settlement administrator, not to wait for a letter. And the wider question remains open: the settlement resolves the claims it covers, but it does not resolve the science. What it does, finally, is put a number and a schedule on a decade of litigation — $7.25 billion, over 21 years, for a product Bayer still insists is safe.







